Notice: This company has been marked as potentially delisted and may not be actively trading. NASDAQ:FWBI First Wave BioPharma (FWBI) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsEarningsHeadlinesInsider TradesShort InterestTrends Get First Wave BioPharma alerts: Email Address About First Wave BioPharma Stock (NASDAQ:FWBI) 30 days 90 days 365 days Advanced Chart Ad Chaikin AnalyticsSell NVDA Now?Guess who's selling NVDA next The most successful hedge fund in history quietly sold 500,000 shares. Here's what that means for your money. Billionaire Wall Street investors are quietly offloading millions of shares. What do they know that you don't? It's arguably the most popular stock in the world. Now, one 50-year Wall Street legend says its day in the sun could finally be coming to an end. Last year, he warned of two stocks that went on to crash 60%.Now he's just issued a warning for the most popular stock in the world: Nvidia (NVDA). Get First Wave BioPharma alerts:Sign Up Key Stats Today's Range N/A50-Day Range$2.60▼$4.6352-Week Range N/AVolume56,500 shsAverage Volume212,944 shsMarket Capitalization$7.34 millionP/E RatioN/ADividend YieldN/APrice Target$36.00Consensus RatingModerate Buy Company OverviewFirst Wave BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the research and development of targeted and non-systemic therapies for the treatment of patients with gastrointestinal diseases. Its product candidates include the biologic adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients; and niclosamide, an oral small molecule with anti-viral and anti-inflammatory properties. The company develops FW-COV, which is in Phase II clinical trials for the treatment of severe acute respiratory syndrome coronavirus 2 gastrointestinal infections; FW-UP, which is in Phase II clinical trials for the treatment ulcerative proctitis and ulcerative proctosigmoiditis; FW-ICI-AC for immune checkpoint inhibitor-associated colitis and diarrhea in advanced stage oncology patients; and FW-UC, which is in Phase Ib/IIa clinical trials for the treatment of ulcerative proctitis and ulcerative proctosigmoiditis. It also develops FW-CD, which has completed Phase I clinical trials for Crohn's disease; and adrulipase, an oral, non-systemic, and biologic capsule for the treatment of exocrine pancreatic insufficiency in patients with cystic fibrosis and chronic pancreatitis. The company was formerly known as AzurRx BioPharma, Inc. and changed its name to First Wave BioPharma, Inc. in September 2021. First Wave BioPharma, Inc. was incorporated in 2014 and is headquartered in Boca Raton, Florida.Read More… Sell NVDA Now? (Ad)Guess who's selling NVDA next The most successful hedge fund in history quietly sold 500,000 shares. Here's what that means for your money. Billionaire Wall Street investors are quietly offloading millions of shares. What do they know that you don't? It's arguably the most popular stock in the world. Now, one 50-year Wall Street legend says its day in the sun could finally be coming to an end. Last year, he warned of two stocks that went on to crash 60%.Now he's just issued a warning for the most popular stock in the world: Nvidia (NVDA). Receive FWBI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for First Wave BioPharma and its competitors with MarketBeat's FREE daily newsletter. Email Address FWBI Stock News HeadlinesENTO Entero Therapeutics, Inc.September 2, 2024 | seekingalpha.comHow to trade Cryptos using Elliott WaveJuly 22, 2024 | fxstreet.comMusk Says ‘Dollar Will Be Worth Nothing…’Elon Musk just issued an urgent warning… It's no secret that Musk is able to move markets with his words…September 17, 2024 | Crypto 101 Media (Ad)Entero Therapeutics to Present Corporate Update at 2024 BIO International ConventionMay 22, 2024 | finance.yahoo.comEntero Therapeutics Presents Two Posters on Celiac Disease Research at the 2024 Digestive Disease Week (DDW) ConferenceMay 20, 2024 | finance.yahoo.comFirst Wave BioPharma Changes Name to Entero TherapeuticsMay 16, 2024 | finance.yahoo.comFWBI Stock Earnings: First Wave BioPharma Beats EPS for Q1 2024May 15, 2024 | investorplace.comFirst Wave BioPharma, Inc. to raise approximately $1.1 million of Gross Proceeds Priced At-the-MarketMay 10, 2024 | globenewswire.comSee More Headlines FWBI Stock Analysis - Frequently Asked Questions How were First Wave BioPharma's earnings last quarter? First Wave BioPharma, Inc. (NASDAQ:FWBI) released its quarterly earnings data on Sunday, November, 14th. The company reported ($13,734.00) earnings per share for the quarter, missing the consensus estimate of ($3,318.00) by $10,416.00. When did First Wave BioPharma's stock split? First Wave BioPharma shares reverse split on Monday, December 18th 2023. The 1-20 reverse split was announced on Monday, December 18th 2023. The number of shares owned by shareholders was adjusted after the market closes on Monday, December 18th 2023. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. Company Calendar Last Earnings11/14/2021Today9/17/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:FWBI CUSIPN/A CIK1604191 Webwww.azurrx.com Phone(561) 589-7020FaxN/AEmployees9Year FoundedN/APrice Target and Rating Average Stock Price Target$36.00 High Stock Price Target$36.00 Low Stock Price Target$36.00 Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-15,800,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-102.83% Return on Assets-22.74% Debt Debt-to-Equity Ratio0.40 Current Ratio1.21 Quick Ratio1.58 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$6.54 per share Price / BookN/AMiscellaneous Outstanding Shares2,480,000Free Float2,463,000Market Cap$7.34 million OptionableNot Optionable Beta1.28 Elon Musk's Next MoveWondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.Get This Free Report This page (NASDAQ:FWBI) was last updated on 9/17/2024 by MarketBeat.com Staff From Our PartnersWar on Elon Escalates… One company holds a near-total monopoly on this technology. Elon Musk is one of the few people who knows th...Porter & Company | SponsoredSell NVDA Now?Guess who's selling NVDA next The most successful hedge fund in history quietly sold 500,000 shares. Here's...Chaikin Analytics | Sponsored44-year Wall Street Vet: “Permanent devastation is coming to America”After 44 years on Wall Street, I've seen it all... Black Monday, the Great Recession, the Covid crash. B...InvestorPlace | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredProtect Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | SponsoredFortune: Nexus Technology has “ignited a gold rush”Business Insider estimates it could grow 8,966% in the near future... And Goldman Sachs says it could grow ...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding First Wave BioPharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share First Wave BioPharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
